Seeing CXCR4 in lymphoma and leukemia with a new PET tracer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective registry study evaluates the safety and diagnostic usefulness of 18F-BL40 PET/CT for staging CXCR4-expressing tumors. Participants will undergo two PET/CT scans: one with 18F-BL40 and another with 18F-FDG, the latter being standard care. The study includes follow-up for at least six months with chart review and phone contacts to monitor any adverse effects and collect outcome data. Manufactured under a Health Canada Clinical Trial Application, 18F-BL40 is assessed alongside routine imaging to determine localization of disease and overall biodistribution. The trial emphasizes safety, feasibility, and potential clinical value of 18F-BL40 in imaging refractory or aggressive hematologic cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥19 years
2. Life expectancy ≥3 months
3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
4. Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers:

   * Diffuse large B-Cell lymphoma
   * Multiple myeloma
   * Mantle cell lymphoma
   * Marginal zone lymphoma
   * Chronic lymphocytic leukemia/small cell lymphoma
   * Waldenström Macroglobulinemia

Exclusion Criteria:

1. Pregnant or breast-feeding
2. Medically unstable (e.g., acute illness, unstable vital signs)
3. Unable to lie supine for the duration of imaging
4. Unable to provide written consent
5. Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm)
6. Participants with a history of uncontrolled allergic reactions and/or known or expected hypersensitivity to the peptide diagnostic \[18F\]BL40 or any of its excipients.

Where it's running

• BC Cancer
  Vancouver, British Columbia, Canada Recruiting

Study contacts

• Principal investigator: Ian Alberts — BC Cancer
• Study coordinator: Pav Ravi
• Email: pavithraa.ravi@bccancer.bc.ca
• Phone: 6048776000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Long-term follow-up of patients receiving CAR-T cell therapy

  This study is tracking patients who have received CAR-T cell therapy for up to 15 years to see how well the treatment works over time and if there are any long-term health issues.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT03375619

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.